Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784 | Completed

• 1 other identifier: IRB: 000000001
• Study Type: observational
• Target: 57
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.

Conditions

Stroke, Ischemic; Stroke Hemorrhagic; Stroke (CVA) or TIA; Stroke, Acute; Traumatic Brain Injury; SCI - Spinal Cord Injury; Ehlers-Danlos Syndromes (EDS); Lupus Erythematosus; Guillain-Barre Syndrome; Multiple Sclerosis; Myasthenia Gravis; Amyotrophic Lateral Sclerosis; Graves Disease; Muscular Dystrophies

Keywords

upper extremity disabilities; limited mobility; dexterity impairments; muscle weakness

Outcome Measures

Primary Outcomes (6)

• Likert Scale

  It is a validated self-reported instrument to assess packaging of the makeup. A few questions will focus on shape of the cap, length of the wand, shape of the doe foot, finish of the components, how it affects grip, and weight of the component/applicator. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

  Complete on Day 7

• Likert Scale

  It is a validated self-reported instrument to assess packaging of the makeup. A few questions will focus on shape of the cap, length of the wand, shape of the doe foot, finish of the components, how it affects grip, and weight of the component/applicator. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

  Complete on Day 14

• Pre-test Questionnaire

  Participants will complete questionnaires that assess their demographics, disability characteristics, and previous experiences with beauty products.

  At baseline

• Accessibility Evaluation

  Participants will evaluate the beauty products based on predefined criteria, including ease of grip, maneuverability, packaging design, and product applicators. They will document their experiences, challenges faced, and any suggestions for improvements. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

  Day 7, after use of beauty products

• Accessibility Evaluation

  Participants will evaluate the beauty products based on predefined criteria, including ease of grip, maneuverability, packaging design, and product applicators. They will document their experiences, challenges faced, and any suggestions for improvements. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

  Day 14, after use of beauty products at end of study

• Post-test Questionnaire

  Participants will assess changes in their perceptions and experiences with the beauty products. This will include questions about satisfaction, usability, and any perceived improvements in accessibility. Possible scores range from 1 (strongly disagree) to 5 (strongly agree).

  Day 14, after use of beauty products at end of study

Study Arms (1)

Minimal to moderate upper extremity deficits

* Individuals aged 18 years to 55 years. * Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments. * Regular users of beauty products. * Able to understand and communicate in the language of the study.

Other: Use of Rare Beauty makeup products

Interventions

Use of Rare Beauty makeup products OTHER

Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.

Minimal to moderate upper extremity deficits

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

A convenience sample of individuals aged 18 and above, with upper extremity deficits, will be recruited for this study. Efforts will be made to include participants with a range of upper extremity deficits and experiences with beauty products.

You may qualify if:

• Individuals aged 18 years to 55 years.
• Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments.
• Regular users beauty products.
• Able to understand and communicate in the language of the study.

You may not qualify if:

• Individuals below 18 years of age or over the age of 55.
• Individuals without upper extremity deficits or with severe upper extremity deficits that may affect the participant's ability to engage in study activities.
• Participants who are not regular users of beauty products.
• Inability to understand and communicate in the language of the study.
• Any medical or psychological condition that may affect the participant's ability to provide informed consent or engage in the study activities safely.
• Individuals who experience facial skin or eye irritation reported by subject or observed by evaluator at baseline visit
• History of allergic reactions, and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc.
• Immunocompromised subjects
• Individuals who may experience changes in hormones, such as just those using oral contraception for less than three months before the screening visit or who have changed hormonal contraceptive methods within the three months before the Baseline visit or planning to modify hormonal contraception treatment within the duration of the study.
• Known to be pregnant, lactating or planning to become pregnant within six months. Subjects who become pregnant during the study must inform the Principal Investigator immediately.

Sponsors & Collaborators

• Casa Colina Hospital and Centers for Healthcare: lead

Study Sites (1)

Casa Colina Hospital and Centers for Healthcare

Pomona, California, 91767, United States

Location

Related Publications (3)

• Skelton H, Gill S, Al Zidjaly N, et al. Exploring the Accessibility of Beauty Products for Individuals with Mobility Disabilities. J Appl Cosmetol. 2020;38(3):65-72.

  BACKGROUND

• Smith A, Johnson R, Thompson A, et al. Enhancing Accessibility: Designing Inclusive Beauty Products for All Abilities. J Inclusive Design. 2021;1(2):89-102

  BACKGROUND

• Chen L, Kim D, Park J, et al. A Review on Product Accessibility Evaluation Methods for People with Disabilities. Int J Ind Ergon. 2019;71:103-117. doi:10.1016/j.ergon.2018.11.007

  BACKGROUND

MeSH Terms

Conditions

Ischemic Stroke; Hemorrhagic Stroke; Stroke; Brain Injuries, Traumatic; Spinal Cord Injuries; Ehlers-Danlos Syndrome; Guillain-Barre Syndrome; Multiple Sclerosis; Myasthenia Gravis; Amyotrophic Lateral Sclerosis; Graves Disease; Muscular Dystrophies; Muscle Weakness

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Wounds and Injuries; Spinal Cord Diseases; Hemostatic Disorders; Hemorrhagic Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Skin Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases; Polyradiculoneuropathy; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Polyneuropathies; Peripheral Nervous System Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Demyelinating Autoimmune Diseases, CNS; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Motor Neuron Disease; TDP-43 Proteinopathies; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases; Exophthalmos; Orbital Diseases; Eye Diseases; Goiter; Thyroid Diseases; Endocrine System Diseases; Hyperthyroidism; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Manifestations; Neurologic Manifestations; Signs and Symptoms

Study Officials

• Emily Rosario, PhD

  Casa Colina Hospital and Centers for Healthcare

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Executive Director

Study Record Dates

• First Submitted: June 27, 2023
• First Posted: July 14, 2023
• Study Start: July 21, 2023
• Primary Completion: September 15, 2023
• Study Completion: September 29, 2023
• Last Updated: December 6, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)